Literature DB >> 22242824

Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007.

Rekha Chandran1, Stuart K Gardiner, Miklos Simon, Stephen E Spurgeon.   

Abstract

A retrospective analysis was done using the Surveillance, Epidemiology, and End-Results (SEER) database to determine the trends in overall survival and identify prognostic factors in patients with mantle cell lymphoma (MCL). In total 5367 cases of MCL identified from 1992 to 2007 were split into three cohorts, group 1(1992-1999), group 2 (2000-2003) and group 3 (2004-2007). Survival was analyzed using the Cox proportional hazards model to correct for age, gender and stage of disease. The proportion of patients with advanced disease at diagnosis, male gender and advanced age increased over time and these were all associated with increased mortality. The overall survival remained unchanged. However, when adjusted for the increased proportion of patients with poor prognostic features noted above, we found a significant improvement in survival. The adjusted model also showed an improvement in predicted survival over time in patients with advanced stage. No change in survival was seen in patients with localized disease. Although this analysis is not designed to evaluate specific treatment modalities, these data suggest that the development of new treatment strategies over the past decade may be impacting the survival of patients with advanced MCL despite the finding that the overall survival remains unchanged in the general US population.

Entities:  

Mesh:

Year:  2012        PMID: 22242824     DOI: 10.3109/10428194.2012.656628

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  31 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

Review 2.  Current approaches and advance in mantle cell lymphoma treatment.

Authors:  Yao Liu; Xi Zhang; Jiang-Fan Zhong
Journal:  Stem Cell Investig       Date:  2015-09-29

Review 3.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Authors:  Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 4.  Bortezomib for the treatment of mantle cell lymphoma: an update.

Authors:  Bryan Hambley; Paolo F Caimi; Basem M William
Journal:  Ther Adv Hematol       Date:  2016-05-21

5.  Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

Authors:  Tiffany Tang; Peter Martin
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

6.  Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Authors:  James N Gerson; Elizabeth Handorf; Diego Villa; Alina S Gerrie; Parv Chapani; Shaoying Li; L Jeffrey Medeiros; Michael I Wang; Jonathon B Cohen; Oscar Calzada; Michael C Churnetski; Brian T Hill; Yazeed Sawalha; Francisco J Hernandez-Ilizaliturri; Shalin Kothari; Julie M Vose; Martin A Bast; Timothy S Fenske; Swapna Narayana Rao Gari; Kami J Maddocks; David Bond; Veronika Bachanova; Bhaskar Kolla; Julio Chavez; Bijal Shah; Frederick Lansigan; Timothy F Burns; Alexandra M Donovan; Nina Wagner-Johnston; Marcus Messmer; Amitkumar Mehta; Jennifer K Anderson; Nishitha Reddy; Alexandra E Kovach; Daniel J Landsburg; Martha Glenn; David J Inwards; Reem Karmali; Jason B Kaplan; Paolo F Caimi; Saurabh Rajguru; Andrew Evens; Andreas Klein; Elvira Umyarova; Bhargavi Pulluri; Jennifer E Amengual; Jennifer K Lue; Catherine Diefenbach; Richard I Fisher; Stefan K Barta
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

Review 7.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

Authors:  Bijal D Shah; Peter Martin; Eduardo M Sotomayor
Journal:  Cancer Control       Date:  2012-07       Impact factor: 3.302

8.  The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.

Authors:  Simon Rule; Paul Smith; Peter W M Johnson; Simon Bolam; George Follows; Joanne Gambell; Peter Hillmen; Andrew Jack; Stephen Johnson; Amy A Kirkwood; Anton Kruger; Christopher Pocock; John F Seymour; Milena Toncheva; Jan Walewski; David Linch
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

9.  Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).

Authors:  Vicki A Morrison; Sin-Ho Jung; Jeffrey Johnson; Ann LaCasce; Kristie A Blum; Nancy L Bartlett; Brandelyn N Pitcher; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2014-08-13

10.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.